The Los Angeles Post
U.S. World Business Lifestyle
Today: March 18, 2025
Today: March 18, 2025

Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia

FILE PHOTO: Logo of German drugmaker Bayer AG in Leverkusen
June 26, 2024
Michael Erman - Reuters

By Michael Erman

NEW YORK (Reuters) - A top Bayer pharmaceutical executive said on Wednesday his group will continue slashing managerial jobs this year, planning cuts in Germany, Japan, the United Kingdom, Belgium and the Netherlands as part of the company's internal reorganization.

The pharmaceutical unit has already cut around 40% of its managerial positions in the U.S. and has also implemented cuts in Canada, Mexico, Italy, Australia and the Nordic countries, Sebastian Guth, chief operating officer of Bayer Pharmaceuticals, said in an interview with Reuters.

Guth would not say exactly how many jobs the company has cut in those countries, but noted that "40% is sort of the range that we tend to see - some are a little lower and some are a little higher."

"We're not shooting for a specific number," Guth said. "For an organization of our size, there's just a lot of work that is being done that ultimately doesn't add value to customers and products."

According to Guth, the reorganization is already paying dividends. For example, the company was able to shave off around a year from its timeline for filing for regulatory approval for its higher dose formulation of its macular degeneration treatment Eylea in Europe.

Regeneron, which sells Eylea in the U.S., received approval for a high-dose version of the drug last year.

Bill Anderson, who became Bayer's CEO in June 2023, announced cuts to management late last year. He has had a tumultuous start, with a continued wave of litigation about an alleged cancer-causing effect of weedkiller glyphosate and a major setback in drug development late last year.

Anderson said in March that he would suspend for up to three years any preparations to break apart the German maker of pharmaceuticals, crop protection products and consumer health remedies.

(Reporting by Michael Erman; Editing by Paul Simao)

Related Articles

Nissan persuades US court to decertify brake defect class actions Boar's Head listeria outbreak is over with 10 dead and dozens sickened by tainted deli meat Daily Mirror publisher faces 101 phone-hacking lawsuits in UK Bayer acquires rights to Cytokinetics' heart drug in Japan
Share This

Popular

Asia|Business|Economy|Finance|Stock Markets

Stock market today: Back down goes Wall Street as Big Tech resumes its slide

Stock market today: Back down goes Wall Street as Big Tech resumes its slide
Business|Political|Technology|US

Judge rules DOGE's USAID dismantling likely violates the Constitution

Judge rules DOGE's USAID dismantling likely violates the Constitution
Business|Political|Travel|US

USDOJ in talks with Southwest Airlines to resolve delayed flights lawsuit

USDOJ in talks with Southwest Airlines to resolve delayed flights lawsuit
Americas|Business|Economy

Chile's economy slows in Q4 but full-year growth beats estimates

Chile's economy slows in Q4 but full-year growth beats estimates

Health

Americas|Economy|Health|Political|World

Millions of people and hundreds of staff impacted by US aid cuts, UN migration agency says

Millions of people and hundreds of staff impacted by US aid cuts, UN migration agency says
Health|Political|US

US HHS drops advisory labeling gun violence a public health crisis

US HHS drops advisory labeling gun violence a public health crisis
Business|Health|Technology|US

FDA classifies recall of Medtronic embolization devices as 'most serious'

FDA classifies recall of Medtronic embolization devices as 'most serious'
Americas|Health|US

Measles cases in Texas, New Mexico rise to 317 as outbreak spreads

Measles cases in Texas, New Mexico rise to 317 as outbreak spreads

Access this article for free.

Already have an account? Sign In